#HealthStocks — Bluesky Posts — bluesky.baby

Profile Explorer

Home New Trending Search

About Privacy Terms

#

#HealthStocks

Posts tagged #HealthStocks on Bluesky

@wallstreetpulse.bsky.social

2 months ago

Theriva Biologics TOVX Technical Analysis and Market Performance

Theriva Biologics TOVX Technical Analysis and Market Performance YouTube video by Hisseseven

#TOVX #TherivaBiologics #StockMarket #BiotechStocks #TechnicalAnalysis #Investing #AMEX #SmallCap #StockAnalysis #RSI #MACD #StockForecasting #HealthStocks #BiologicalTreatments #DayTrading #FinanceNews #HoldRating #MarketIndicators #StockUpdate #InvestmentStrategy youtu.be/wbPdAXT_ofw

2 0 0 0

@deveregroup.bsky.social

5 months ago

💊 Health Check: “A tariff of this magnitude on high-value medicines will ripple through every part of the global health economy,” says our CEO @nigeljgreen.bsky.social 🧬

stockhead.com.au/health/healt... @stockheadau.bsky.social

#Biotech #Pharma #Investing #HealthStocks #Trump

0 0 0 0

@georgeprior.bsky.social

5 months ago

💊 Health Check: “A tariff of this magnitude on high-value medicines will ripple through every part of the global health economy,” says deVere's @nigeljgreen.bsky.social 🧬

stockhead.com.au/health/healt... @stockheadau.bsky.social

#Biotech #Pharma #Investing #HealthStocks #Trump

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know - uk.finance.yahoo.com Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know uk.finance.yahoo.com

Click Subscribe #HealthStocks #StockMarket #Investing #FinanceNews #Healthcare

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

‘Barron’s Roundtable’ analyzes struggling health stocks - Fox Business ‘Barron’s Roundtable’ analyzes struggling health stocks Fox Business

Click Subscribe #HealthStocks #StockMarket #Investing #FinanceNews #MarketAnalysis

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Enovis, CONMED, Astrana Health, Privia Health, and Waters Corporation Stocks Trade Down, What You Need To Know - Yahoo Finance Enovis, CONMED, Astrana Health, Privia Health, and Waters Corporation Stocks Trade Down, What You Need To Know Yahoo Finance

Click Subscribe #StockMarket #Investing #FinanceNews #EconomicTrends #HealthStocks

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

9 months ago

2 Weight Loss Drug Stocks That Are Screaming Buys in June - The Motley Fool 2 Weight Loss Drug Stocks That Are Screaming Buys in June The Motley Fool

Click Subscribe #WeightLoss #HealthStocks #Investing #WeightLossDrugs #Pharmaceuticals

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

9 months ago

Hims & Hers Health: Analysts remain bearish Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate. In a note Thursday, Citi flagged potential pressure from Evernorth’s newly announced benefit that caps patient out-of-pocket costs for GLP-1 drugs Wegovy and Zepbound at $200 per month, well below the $599 per month pricing offered through Hims’ new NovoCare partnership. “To the extent we see plan sponsors adopt this offering, we do think that this will be a slight headwind to HIMS’ newly announced NovoCare partnership,” Citi said. They noted that Evernorth’s model may also appeal to employers, as it could simplify access and help shift patient costs toward insurance. The bank kept its Sell rating and $30 per share target price for the stock. Bank of America echoed concerns about sustainability. They note that April data showed a 6% sequential decline in total sales and the second consecutive month of lower GLP-1 sales. “Revenue growth ex-GLP-1s has slowed significantly,” BofA wrote, citing increased ad focus on GLP-1 offerings, rising competition, and softer returns from long-duration subscriptions. The firm also warned that regulatory scrutiny on compounded semaglutide could cloud Hims’ FY25 outlook. “The ability to meet the FY25 guide hinges on the scale of personalized GLP-1s,” BofA wrote, noting that the upcoming end of the 503B compounding grace period could prompt FDA or Novo Nordisk (NYSE:NVO) action. BofA maintained an Underperform rating and $28 price target on HIMS.

Click Subscribe #HimsAndHers #HealthStocks #StockMarket #InvestmentNews #BearishMarket

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

10 months ago

Goldman Sachs says this little-known health stock can withstand volatile macro environment, rise more than 35% - CNBC Goldman Sachs says this little-known health stock can withstand volatile macro environment, rise more than 35% CNBC

Click Subscribe #GoldmanSachs #HealthStocks #Investing #StockMarket #FinanceNews

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

10 months ago

TD Cowen downgrades Hims & Hers Health to Hold on GLP-1 headwinds, Investing.com -- TD Cowen downgraded Hims & Hers Health to "Hold" from "Buy" citing a lack of near-term catalysts and concerns over the company’s weight loss revenue guidance in a post-compounded GLP-1 environment. Separately, Hims Hers Health shares surged after the telehealth group announced a "long-term collaboration" with Novo Nordisk (NYSE:NVO) A/S to offer the Danish firm’s blockbuster Wegovy obesity drug on its platform. Upside to the remainder of the year could be limited after a strong 1Q25E EPS, analysts wrote, noting compounded GLP-1s are no longer offered beyond May 22, TD said. The firm expects a Q1 beat, driven by demand for compounded GLP-1s, but warned that comparisons remain tough throughout 2025 and 2026. TD Cowen flagged three main risks: potentially optimistic weight loss revenue guidance of $725 million for FY25, uncertainty around patient switching behavior to alternative therapies like Liraglutide and oral meds, and an intensifying competitive landscape with platform like Lilly Direct. It also pointed to broader recession risks and muted consumer demand as factors to monitor. Despite high short interest of around 34%, the analysts believe estimates will likely come down for both FY25 and FY26, presenting downside risk. The price target was lowered to $30, based on ~2.6x FY2 EV/Sales. We move to the sidelines as near-term upside may be limited but we like the story for the long-term as HIMS remains committed to making healthcare accessible for all

Click Subscribe #HimsAndHers #TDcowen #HealthStocks #StockMarket #InvestingNews

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

11 months ago

How RFK Jr. Is Going 'Wild' On Health And Biotech Stocks - Investor's Business Daily How RFK Jr. Is Going 'Wild' On Health And Biotech Stocks Investor's Business Daily

Click Subscribe #RFKJr #HealthStocks #Biotech #Investing #StockMarket

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

11 months ago

UnitedHealth, Humana and other health-insurance stocks are surging after this ‘big win’ - MarketWatch UnitedHealth, Humana and other health-insurance stocks are surging after this ‘big win’ MarketWatch

Click Subscribe #HealthInsurance #Investing #StockMarket #FinanceNews #HealthStocks

0 0 0 0